drugset / Trial / NCT06378593
A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
Non-randomizedSequentialOpen-labelTreatment
Summary
The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations.
Timeline
- Start
- 2024-06-17
- Primary completion
- 2028-06-16
- Completion
- 2028-06-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 3HP-2827 | Unknown | — | Oral |